– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million –

– Capital now available to support continued growth of the YCANTH® business and advancement of the Company’s global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1’27 –

WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it has achieved the pre-defined revenue, growth and operational milestones required to increase the maximum commitment amount under its credit facility with an entity controlled by Paul B. Manning, Chairman and Chief Executive Officer of PBM Capital and Chairman of Verrica’s Board of Directors. As a result of the achievement of these milestones, the full $27.5 million of non-dilutive capital under the facility is now available to Verrica, with the first $12.5 million having been funded in September.

“Verrica’s achievement of these milestones resulted directly from the momentum our team has built with YCANTH,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “We committed to clear revenue, growth and operational goals when we closed this facility in August, and we delivered on them. Importantly, the capital now available to Verrica by this facility allows us to complete our two pivotal studies in the common warts program, with readouts from the studies expected in the first quarter and in mid-2027, respectively. Under the facility, we have no obligation to make scheduled principal or interest cash payments during the term of the facility, and the favorable covenant package allows us to fully utilize our cash to support our growth. On behalf of all of us at Verrica, I would like to again thank Paul Manning for his confidence in our progress and for providing this highly flexible funding to support our programs.”

“Verrica’s execution over the past several months reinforces my confidence in the team and in YCANTH,” said Paul B. Manning, Chairman of Verrica’s Board of Directors. “I am pleased to continue supporting the Company as it builds on this progress.”

Terms of the Credit Agreement

Under the terms of credit agreement, Verrica may borrow up to $27.5 million from time to time, at its option. Borrowings under the facility will bear interest at the one-month secured overnight financing rate (SOFR) plus 8.00% per annum, subject to a SOFR floor of 4.50%. All interest under the facility will be payable in kind, subject to the absence of any event of default under the credit agreement (which results in interest being payable in cash and increased during the pendency of such event of default, unless otherwise elected by the lender). The term loans will mature on December 31, 2030. The credit agreement also requires mandatory prepayments with the proceeds of certain transactions and events, and quarterly payments if positive operating cash flow exceeds a specified amount. The credit facility is secured by substantially all of the assets of Verrica and certain subsidiaries.

About YCANTH® (VP-102) 

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum.

Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay as little as $0 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

YCANTH is also approved for the treatment of molluscum contagiosum in Japan and is being studied in a global phase 3 program in the US and Japan for the treatment of common warts.

About Verrica Pharmaceuticals Inc. 

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrica’s ability to borrow funds under the credit facility, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, the timing of readouts from the Phase 3 common warts program and Verrica’s cash runway. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — GPGI, Inc. (NYSE: GPGI), a diversified multi-industry platform for companies with great positions in good industries, today announced it will host a conference call on Thursday, November 5, 2026, at 8:00 a.m. Eastern Standard Time (EST) to discuss its financial results for the third quarter ended September 30, 2026. GPGI’s earnings results will be reported in a press release prior to the call.

GPGI’s leadership team will host the conference call, followed by a question-and-answer session.

Date: Thursday, November 5, 2026
Time: 8:00 a.m. EST
Live webcast registration link: here

We encourage all participants to register at least 15 minutes prior to the 8:00 a.m. EST start time. A live webcast and replay will be available on GPGI’s website at https://gpgi.com/events-presentations/. If you have any difficulty registering for the conference call, please contact GPGI at ir@gpgi.com.

About GPGI

GPGI, Inc. (NYSE: GPGI) is a diversified, multi-industry platform for companies with great positions in good industries. The platform is managed by Resolute Holdings Management, Inc. (NYSE: RHLD) and is purpose-built to acquire, own, and scale high-quality businesses led by great operators, benefiting from a permanent capital base and the systematic deployment of the Resolute Operating System. GPGI currently consists of CompoSecure and Husky – two market leaders with best-in-class financials and durable opportunities for growth. For more information, please visit GPGI.com.

GPGI Contact
ir@gpgi.com

Segment to air Sunday, October 25, at 5:30 p.m. ET on Fox Business Network

CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it will be featured on Health Uncensored with Dr. Drew, a national health television series hosted by Dr. Drew Pinsky, in a segment on non-invasive approaches to delivering investigational therapies to brain tumors.

Fox Business Network will carry the segment on Sunday, October 25, 2026, at 5:30 p.m. ET / 2:30 p.m. PT. Air dates and times are subject to change.

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer, and Thomas Chen, MD, PhD, Founder, Chief Medical Officer and Chief Scientific Officer of NeOnc, join Dr. Drew to discuss how NeOnc’s intranasal approach is designed to reach brain tumors directly, without the limitations of surgery and systemic chemotherapy.

During the segment, Mr. Heshmatpour describes brain cancer as a growing problem and discusses the Company’s investigational intranasal NEO100 program, which is in clinical development in both adults and children. Speaking about what the program could mean for patients, he says: “We believe that we will make a significant impact in the standard of care for adults and kids suffering with brain cancer.”

Additionally, in the segment, Dr. Chen explains how the same mechanism meant to protect the brain actually makes brain tumors so difficult to treat with traditional approaches, and how NeOnc is working to overcome that challenge.

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established.

About Health Uncensored with Dr. Drew

Health Uncensored with Dr. Drew is a health and wellness program hosted by Dr. Drew Pinsky, a board-certified physician in Internal and Addiction Medicine, as well as a television host, author and public speaker. Dr. Drew engages with a range of experts, thought leaders, celebrities and everyday people to provide viewers with practical advice, evidence-based information and discussions about wellness, mental health and the importance of proactive health management.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches.

For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s clinical development programs and the clinical potential of NEO100. These statements reflect current expectations and involve risks and uncertainties. NEO100 is investigational and has not been approved by any regulatory authority; future studies may not demonstrate safety or efficacy; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release.

The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

This press release was published by a CLEAR® Verified individual.

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.

To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

Nasdaq closes reporting deficiency following filing of second-quarter 2026 Form 10-Q

FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.

Nasdaq’s determination follows Celularity’s October 20, 2026 filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2026. Nasdaq confirmed that the reporting deficiency matter is now closed.

As previously disclosed, on September 11, 2026, Nasdaq confirmed that Celularity had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2), closing both matters. With today’s notification, each of these three previously disclosed deficiency matters has been closed.

“We have repeatedly fallen short of our obligation to provide timely financial reporting, and I take responsibility for that,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “Our shareholders deserve better. With our filings now current, we must address the recurring delays. We have begun a process to overhaul our finance organization and establish the reporting discipline expected of a public company.”

“The need to strengthen the finance organization was clear when I invested in Celularity, and the late filings did not change my conviction in Celularity’s science and commercial potential,” said Philip A. Barach, a recently appointed director and investor in Celularity. “The Board is working with Dr. Hariri to identify experienced finance professionals who can carry that work forward. Our focus is on building a team that can consistently meet ongoing financial reporting obligations as we aggressively pursue the opportunities ahead.”

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Its cellular therapy portfolio includes cenplacel-L, its investigational placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built cGMP research and manufacturing facility supporting the development and manufacture of cellular therapies, advanced biomaterials and other longevity and wellness-focused products.

For more information, visit www.celularity.com.

Forward-Looking Statements

This release contains forward-looking statements under applicable federal securities laws, including statements concerning Celularity’s finance organization overhaul, expected improvements in financial reporting, ability to maintain compliance with Nasdaq listing requirements, and execution of its regenerative longevity strategy. These statements reflect management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. Such risks include Celularity’s ability to implement organizational and reporting improvements, maintain sufficient resources to meet its reporting obligations, and satisfy continued listing requirements, together with other risks described in Celularity’s SEC filings. Celularity undertakes no obligation to update these statements except as required by law.

Contact

info@celularity.com

The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness

SPRING BRANCH, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today is providing shareholders with a timeline to break ground on an intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. The $16 million facility will be fully funded by a third party through a non-dilutive, non-interest-bearing partnership.

The Company recently announced formal approval of blueprints for the construction and expects to break ground before the end of October. Once the construction is complete and the facility becomes fully operational, it is projected to generate $450 million in annual revenue, including $300 million from standard IV bags and $150 million from premixed drug IV bags.

The facility is planned within the Marion 9 Biomanufacturing Center at the Atlas Complex and demonstrates Callan JMB’s previously announced pharmaceutical manufacturing initiative with Alabama State University. The blueprint approval significantly advanced the project and provided the design basis to break ground to construct a state-of-the-art facility combining automated production with quality-control and advanced distribution capabilities.

“Achieving blueprint approval was a critical milestone, and we are moving quickly to break ground and begin construction on the facility this month. This facility is backed fully by a third-party investment that will not add debt to Callan JMB’s balance sheet nor is dilutive to Callan JMB shareholders. This project builds on our healthcare logistics and emergency-preparedness experience while supporting the strengthening of the United States (U.S.) domestic pharmaceutical production, enhancing U.S. supply chain resilience, and improving national security through medical preparedness,” said Wayne Williams, Callan JMB’s Chief Executive Officer.

About Callan JMB Inc.

Callan JMB Inc. (NASDAQ: CJMB) is a diversified logistics, preparedness, and critical-infrastructure company supporting healthcare organizations, government agencies, and commercial partners. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, and emergency-preparedness services designed to protect critical products, strengthen supply chains, and support continuity of operations. Through its businesses and strategic partnerships, Callan JMB is building a broader platform spanning healthcare and pharmaceutical logistics, domestic manufacturing, and critical electrical infrastructure. For more information, visit www.callanjmb.com.

Investor Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

Media Contact
Arian Hopkins
ahopkins@callanjmb.com

About the Atlas Complex by Callan JMB

Atlas Complex by Callan JMB is a pharmaceutical, medical, and logistics campus located in Marion, Alabama. Designed to support U.S. pharmaceutical onshoring and strengthen domestic supply chains, the campus provides scalable infrastructure for pharmaceutical manufacturing, quality assurance and quality control (QA/QC), research collaboration, workforce development, cold chain logistics, and domestic distribution within a single integrated environment.

Atlas Complex Media Contact
Arian Hopkins
ahopkins@callanjmb.com

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by, or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November:

Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY)
Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th. Click here to access the live webcast.

20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum – November 11, 2026 (New York, NY)
Management will present at 10:30 am ET and will host one-on-one meetings with investors on Wednesday, November 11th. Click here to access the live webcast.

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

GRAPEVINE, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Solo Brands, Inc (OTCQB: SBDS), (“Solo Brands” or the “Company”), an omni-channel platform of beloved brands Solo Stove, Chubbies, Oru Kayak, and ISLE, today announced that it plans to report its fiscal third quarter results on November 12, 2026, before the market opens. In conjunction with the release, the Company has scheduled a conference call for management’s prepared remarks on Solo Brands strategy and financial results that will begin at 9:00 a.m. ET.

Investors and analysts are invited to listen to the call by dialing 1-866-652-5200 (international callers, please dial 1-412-317-6060) at least 10 minutes prior to the start and ask to join the Solo Brands call. A live webcast of the conference call will be available in the investor relations section of the Company’s website, https://investors.solobrands.com.

A recorded replay of the call will be available shortly after the conclusion of the call and will remain available until November 19, 2026. To access the telephone replay, dial 1-855-669-9658 (international callers, please dial 1-412-317-0088). The access code for the replay is 8833822. A replay of the webcast will also be available shortly after the conclusion of the call and will remain available for one year.

About Solo Brands, Inc.

Solo Brands, headquartered in Grapevine, TX, is a leading omnichannel lifestyle brand company. Leveraging e-commerce, strategic retail relationships and physical retail stores, Solo Brands offers innovative products to consumers through four lifestyle brands – Solo Stove, known for firepits, stoves, and accessories; Chubbies, a premium casual apparel and activewear brand; ISLE, maker of inflatable and hard paddle boards and accessories; and Oru Kayak, innovator of origami folding kayaks.

Company Contact:
Mark Anderson, Senior Director of Treasury & Investor Relations
investors@solobrands.com

Investor Relations Contact:
Sandy Martin and Steven Hooser
Three Part Advisors, LLC
214-616-2207 / 214-872-2710

Source: Solo Brands, Inc.

Fusion Fuel to Issue 500,000 of its Nasdaq-Listed Class A Ordinary Shares to the Al Shola Gas Minority Shareholders, Subject to Closing Conditions, to Satisfy $2.0 Million of QIND’s Purchase Price, in Exchange for $2.0 Million of QIND Common Stock

Restructuring Removes QIND’s Debt Financing, Credit Facility, Equity Line and Bank Guarantee Commitments, Introduces Quarterly Dividends from Al Shola Gas and Grants QIND an Option to Acquire Al Shola Gas Individual Shareholders’ 49% Ownership Interest

San Francisco, CA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Quality Industrial Corp. (OTCID: QIND) (“QIND” or the “Company”), an industrial energy company specializing in liquefied petroleum gas (“LPG”) infrastructure and distribution, today announced that it has entered into an Agreement and Amendment No. 2 to the Share Purchase Agreement, dated as of September 23, 2026 (the “Amendment”), with Al Shola Al Modea Gas Distribution L.L.C. (“Al Shola Gas”) and the three individual shareholders of Al Shola Gas who together hold 49% of Al Shola Gas (the “ASG Shareholders”). The Amendment amends the Share Purchase Agreement dated March 27, 2024, under which QIND acquired 153 of the 300 shares, or 51%, of Al Shola Gas, as previously amended on April 8, 2025 (together, the “SPA”).

Concurrently with the Amendment, QIND entered into a Share Exchange Agreement, dated as of September 23, 2026 (the “Share Exchange Agreement”), with its majority shareholder, Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel”). Under that agreement, and subject to its closing conditions, Fusion Fuel will issue an aggregate of 500,000 of its Class A Ordinary Shares (calculated by dividing $2.0 million by a price per share of $4.00, subject to adjustment for any share consolidation, share split, share dividend or similar event) to the ASG Shareholders, which issuance will satisfy $2.0 million of QIND’s remaining purchase price under the Amendment, and QIND will issue $2.0 million of its common stock to Fusion Fuel as consideration.

Fusion Fuel’s Role in Satisfying $2.0 Million of the Purchase Price

Under the Amendment, $2.0 million of the purchase price is to be satisfied by the issuance of Fusion Fuel’s Class A Ordinary Shares to the ASG Shareholders pursuant to the Share Exchange Agreement, and that portion will not be deemed paid unless and until the shares are actually issued or the Alternative Payment described below is made. Fusion Fuel’s Class A Ordinary Shares are listed on The Nasdaq Stock Market LLC (“Nasdaq”). Fusion Fuel is not a party to the SPA or the Amendment.

As consideration, QIND will issue to Fusion Fuel shares of its common stock with an aggregate value of $2.0 million. The number of shares will be $2.0 million divided by the lower of (i) the closing price of QIND’s common stock immediately preceding the closing date and (ii) the average closing price for the five trading days ending on the trading day immediately preceding the closing date, rounded to the nearest whole share. If the closing under the Share Exchange Agreement occurs, the issuance of the Fusion Fuel shares will satisfy this $2.0 million portion of the purchase price.

Carsten Kjems Falk, Chief Executive Officer and Interim Chief Financial Officer of QIND, commented: “This is a milestone for QIND. The Amendment provides for quarterly dividend distributions from Al Shola Gas commencing from the third quarter of 2026, unless otherwise determined by the Al Shola Gas Board of Directors, which we believe could provide for cash generated by Al Shola Gas to be used by QIND for payment of its obligations and other working capital and general corporate purposes.”

“Under the amended terms, $2.0 million of the purchase price will be satisfied through Fusion Fuel’s issuance of its Nasdaq-listed shares to the Al Shola Gas shareholders, and QIND will issue its own shares to Fusion Fuel in exchange, which we believe further aligns our two companies. Together with the removal of the legacy financing commitments, the 2027 payment schedule, quarterly dividends from Al Shola Gas and our option over the 49% ownership of Al Shola Gas held by the ASG Shareholders, we believe this restructuring puts QIND’s ownership of Al Shola Gas on a firmer footing and resolves any actual or alleged prior defaults under the SPA through the mutual waiver and release.”

Restructured Purchase Price

The total purchase price for QIND’s 51% interest in Al Shola Gas remains $10.0 million. Following the restructuring, and assuming the $2.0 million portion is satisfied through the closing under the Share Exchange Agreement or the Alternative Payment, $6.98 million remains payable on or before December 31, 2027.

Component   Amount     Form of payment   Timing
Previously paid   $ 1,020,000     Cash   Received by the ASG Shareholders
Fusion Fuel shares   $ 2,000,000     500,000 Fusion Fuel Class A Ordinary Shares at $4.00 per share (subject to adjustment), or the Alternative Payment if the closing under the Share Exchange Agreement has not occurred by December 31, 2026   At closing of the Share Exchange Agreement
2027 payment   $ 6,000,000     Any form determined by QIND in its sole discretion, including cash or securities of QIND, its affiliates or any other person, provided any securities are listed on a securities exchange when delivered   On or before December 31, 2027
Cash payment   $ 980,000     Cash   On or before December 31, 2027
Total   $ 10,000,000          

All purchase price payments are allocated 40% / 40% / 20% among the ASG Shareholders, as above. QIND’s obligation to make the $2.0 million, $6.0 million and $980,000 payments is conditioned on (i) the ASG Shareholders having complied in all material respects with their cooperation obligations for the Share Exchange Agreement closing, and (ii) either that closing having occurred or QIND having made the Alternative Payment.

Additional Terms Benefiting QIND

  • Removal of financing commitments. QIND’s former obligations to provide or arrange debt financing, credit facilities, equity lines, credit lines or bank guarantees for the benefit of Al Shola Gas or the ASG Shareholders are of no further force or effect.
  • Narrowed working capital obligation. The prior working capital provisions are replaced by an obligation to use commercially reasonable efforts to facilitate Al Shola Gas’s purchase of one additional LPG bobtail vehicle of approximately 18,000 liters by December 31, 2026. Al Shola Gas selects the vendor and provides all funds. QIND has no obligation to finance, advance or guarantee any amount.
  • Waiver, release and full satisfaction. The parties mutually waive and release claims relating to any actual or alleged prior defaults under the SPA, including on the timing, amount or form of purchase price payments, the working capital and vehicle obligations, and the debt financing obligations. The ASG Shareholders acknowledge that the restructured purchase price, including the issuance of the Fusion Fuel shares or, if applicable, the Alternative Payment, the revised payment schedule and the deletion of the financing obligations, collectively constitute full and complete satisfaction of all of QIND’s obligations under the SPA arising before the date of the Amendment.
  • Quarterly dividends. Al Shola Gas will make quarterly dividend distributions equal in aggregate to its Profits (as defined in the Amendment) for the previous fiscal quarter, pro rata to equity interests, starting from the third quarter of 2026, unless its Board of Directors determines otherwise. QIND’s pro rata share corresponds to its 51% interest.
  • Call option on the 49% held by the ASG Shareholders. Each ASG Shareholder grants QIND an irrevocable option, exercisable at QIND’s sole discretion on or before March 27, 2027, to buy all or any portion of their Al Shola Gas shares at $65,359.48 per share. That price matches the original $10.0 million valuation for 51%; for all 147 remaining shares it equals approximately $9.61 million. Payment may be made in any form permitted for the purchase price.
  • Right of first refusal. QIND has a 30-day right of first refusal, on the same terms, over any proposed transfer of Al Shola Gas shares by an ASG Shareholder to a third party.
  • Longer restrictive covenants. The period of the ASG Shareholders’ confidentiality, non-competition and non-solicitation restrictions under Section 7.01 of the SPA is extended from two years to four years.
  • Cost sharing. From the third quarter of 2026, the Al Shola Gas Board of Directors may determine that certain costs paid by QIND for Al Shola Gas, including audit fees and administrative expenses, will be shared between Al Shola Gas and QIND.
  • Transfer restrictions controlled by QIND. The Fusion Fuel shares and any other securities delivered to the ASG Shareholders as purchase price are subject to a six-month lock-up, during which they may not be transferred without QIND’s prior written consent. A leak-out then limits each ASG Shareholder’s sales on any trading day to 3% of that day’s total trading volume. Fusion Fuel has agreed to file a registration statement covering the resale of the Fusion Fuel shares no later than 30 calendar days following closing; the filing or effectiveness of the registration statement will not affect the lock-up and leak-out restrictions.

QIND and Fusion Fuel have also mutually waived and released claims arising from their entry into and performance of these agreements, including under the Stock Purchase Agreement dated November 18, 2024 among QIND, Fusion Fuel, Ilustrato Pictures International Inc. and other sellers, solely with respect to these transactions.

Closing Conditions and Alternative Payment

Closing of the Share Exchange Agreement is subject to conditions that, except for a limited ability to waive the accuracy of representations and warranties, the parties cannot waive. These include Nasdaq’s approval of an initial listing application in connection with the transactions contemplated by the November 18, 2024 Stock Purchase Agreement and the issuance of the Fusion Fuel shares, and receipt of all required governmental approvals, including any Nasdaq approvals and any approvals required under the Irish Takeover Panel Act 1997, Takeover Rules. QIND must also deliver accredited investor questionnaires and AML/KYC documentation for each ASG Shareholder. Fusion Fuel is not required to submit or pursue an initial listing application with Nasdaq unless it determines, in its sole discretion, that it will meet the applicable listing requirements at the time.

If the Fusion Fuel shares have not been issued on or before December 31, 2026 because the closing unde the Share Exchange Agreement has not occurred, QIND must, within ten calendar days thereafter, satisfy the $2.0 million portion by paying $2.0 million in cash or delivering other exchange-listed securities valued at $2.0 million in accordance with the Amendment (the “Alternative Payment”).

The foregoing summary is qualified in its entirety by the full text of the Amendment and the Share Exchange Agreement, which QIND has filed as exhibits to a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) on September 25, 2026.

About Quality Industrial Corp.

Quality Industrial Corp. (OTCID: QIND) is an industrial energy company specializing in LPG infrastructure and distribution and a majority-owned subsidiary of Fusion Fuel Green PLC. Through its majority-owned subsidiary, Al Shola Gas, QIND provides consulting, engineering, installation, maintenance and LPG supply services to residential, commercial and industrial customers across the United Arab Emirates.

About Fusion Fuel Green PLC

Fusion Fuel Green PLC (Nasdaq: HTOO) is a diversified energy platform offering a comprehensive suite of energy supply, distribution, and engineering and advisory solutions through its operating businesses Al Shola Gas, Bright Hydrogen Solutions Ltd (“BrightHy Solutions”) and Biosteam Energy (Proprietary) Limited (“BioSteam Energy”). Al Shola Gas provides full-service industrial LPG solutions, including the design, supply, and maintenance of LPG systems, as well as the transport and distribution of LPG across commercial, industrial, and residential sectors. BrightHy Solutions, the Company’s hydrogen solutions platform, delivers engineering and advisory services enabling decarbonization across hard-to-abate industries. BioSteam Energy provides biomass-powered industrial steam solutions to clients. Through Royal Uranium Inc., the Company also holds a portfolio of uranium and natural gas royalty and other interests across Canada, Colombia and Argentina. For more information, please visit www.fusion-fuel.eu.

Forward-Looking Statements

This press release contains forward-looking statements, which involve risks and uncertainties. Forward-looking statements generally relate to future events or QIND’s future financial or operating performance and can be identified by words such as “may,” “will,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” “plan,” “target,” “predict,” “potential,” or the negative of such terms, or other comparable terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding: the anticipated issuance of 500,000 Fusion Fuel Class A Ordinary Shares to the ASG Shareholders and of QIND common stock to Fusion Fuel, and the timing of the closing under the Share Exchange Agreement; the satisfaction of the closing conditions under the Share Exchange Agreement; the expected reduction of QIND’s remaining purchase price obligations; the payment of the remaining purchase price on or before December 31, 2027 and any Alternative Payment; the anticipated quarterly dividend distributions by Al Shola Gas and the use of cash generated by Al Shola Gas; any exercise of the call option or right of first refusal; any cost sharing between Al Shola Gas and QIND; QIND’s facilitation of the purchase of an additional LPG bobtail vehicle by Al Shola Gas; the anticipated filing and effectiveness of a resale registration statement by Fusion Fuel; and the expected benefits of the transactions to QIND, including the alignment of QIND and Fusion Fuel and the strengthening of QIND’s ownership of Al Shola Gas. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

These forward-looking statements are based on current expectations and assumptions and are not guarantees of future performance, conditions, or results. They involve known and unknown risks, uncertainties, and other important factors, many of which are outside QIND’s control, that could cause actual results to differ materially from those expressed or implied, including, without limitation: the risk that the closing conditions under the Share Exchange Agreement, including Nasdaq approval of an initial listing application (which Fusion Fuel is not required to submit unless it determines that it will meet the applicable Nasdaq listing requirements) and any approvals required under the Irish Takeover Panel Act 1997, Takeover Rules, are not satisfied in a timely manner or at all; the risk that QIND is unable to issue the required number of shares of its common stock at closing; QIND’s ability to make the Alternative Payment within ten calendar days after December 31, 2026 if the closing under the Share Exchange Agreement has not occurred; QIND’s ability to pay the remaining $6.98 million on or before December 31, 2027; dilution to QIND’s stockholders from the issuance of common stock to Fusion Fuel at the lower of the prior closing price and the five-day average closing price; QIND’s ability to fund any exercise of the call option; the material uncertainty regarding QIND’s ability to continue as a going concern, including QIND’s matured and unpaid convertible notes and its dependence on external financing, including from Fusion Fuel; the risk that Al Shola Gas does not generate Profits sufficient to support dividend distributions, or that its Board of Directors determines not to make them; the risk that the bobtail vehicle purchase is not completed; the risk that the resale registration statement is not filed or declared effective within the required timeframes; geopolitical instability or armed conflict in the Middle East, including disruptions to shipping through the Strait of Hormuz and the departure of customers from the region, that could disrupt Al Shola Gas’s operations, sales volumes, supply chain and costs in the United Arab Emirates; fluctuations in LPG and other energy commodity prices; foreign currency fluctuations; and the risks and uncertainties described in QIND’s Annual Report on Form 10-K filed with the SEC on March 31, 2026, and its other filings with the SEC. Actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. All forward-looking statements in this press release are qualified in their entirety by the cautionary statements above. QIND does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances that may arise after the date hereof, except as required by law.

Contact

Quality Industrial Corp. 505 Montgomery Street, San Francisco, CA 94111 Phone: +1-800-706-0806 Email: info@qualityindustrialcorp.com Investor Relations Website: qualityindustrialcorp.com X: @QualityIndCorp | @Fusion_Fuel

Source: Quality Industrial Corp.

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Presentation details:

  1. Title: “Restoring proteostasis in Alzheimer’s disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins”
     
    • Presenter: Alexander Morin, PhD, Director, Strategic Communications
    • Type: Oral communications
    • Section: Biotech Showcase 7
    • Date & time: November 19, 3:52 p.m. ET

  2. Title: “Clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients”
    • Presenter: Cheng Fang, PhD, Chief Scientific Officer
    • Type: Poster presentation (P025)
    • Section: Clinical Trials – Phase IIB & III
    • Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET

  3. Title: “Predicting blood–brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer’s disease using artificial intelligence”
    • Presenter: Alexander Morin, PhD, Director, Strategic Communications
    • Type: Poster presentation (P121)
    • Section: AI-Driven Innovation in Alzheimer’s Therapeutics
    • Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET

“Three presentations at CTAD are a testament to our team’s work advancing buntanetap and pushing the Alzheimer’s field forward,” said Maria Maccecchini, PhD, Founder, President and CEO of Annovis. “Our presentations will cover buntanetap’s innovative mechanism of action, our use of AI for evaluating the Alzheimer’s treatment pipeline, and the updates on our pivotal Phase 3 study in early AD. Together, they reflect our progress as we approach a pivotal data readout in early 2027 and prepare for a New Drug Application. We look forward to sharing all this work and connecting with the Alzheimer’s research community.”

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.